查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1612194

抗體契約製造市場：按抗體類型、來源、服務和最終用戶分類 - 2025-2030 年全球預測

Antibodies Contract Manufacturing Market by Antibody Type (Monoclonal Antibodies, Polyclonal Antibodies), Source (Mammalian, Microbial), Services, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年抗體契約製造市場價值為163.4億美元，預計到2024年將達到180.4億美元，複合年成長率為10.82%，到2030年將達到335.6億美元。

在抗體契約製造中，我們將治療、診斷和研究所必需的抗體的生產委託給專門的第三方組織。慢性疾病的日益普及、個人化醫療的日益重要性以及對新型療法的需求推動了對抗體製造的需求，這些因素共同推動了對可擴展且可靠的製造能力的需求。應用範圍涵蓋製藥、生物技術、學術研究和診斷，最終用途主要用於治療性單株抗體、多株多株抗體、生物相似藥和抗體片段。關鍵的成長要素包括生物技術的進步、生技藥品的興起以及全球醫療基礎設施的擴張。此外，高通量篩檢和改進的表達系統等技術創新正在推動市場擴張。目前的機會存在於新興國家的開拓市場，這些國家對先進醫療保健解決方案的需求不斷增加，以及雙特異性抗體和抗體藥物複合體等利基市場。為了抓住這些機會，公司必須注重策略夥伴關係和產能擴張，以滿足對不同類型抗體不斷成長的需求。然而，市場面臨嚴格的法律規範、複雜的製造流程、高製造成本和智慧財產權問題等挑戰。透過有效的品管系統和簡化的生產技術解決這些障礙可以降低風險。改進的表現系統（例如 CHO 細胞）、永續製造方法以及透過人工智慧進行的流程最佳化等創新提供了取得重大進展的潛力。生物相似藥抗體和個人化醫療解決方案的探索也提供了重要的成長途徑。整體而言，這個市場的特徵是技術進步快、競爭動態，要求企業不斷創新和適應。透過專注於永續、業務效率和全球企業發展，企業可以在這一繁榮中佔據有利地位。

主要市場統計
基準年[2023] 163.4億美元
預計年份 [2024] 180.4億美元
預測年份 [2030] 335.6億美元
複合年成長率（%） 10.82%

市場動態：快速發展的抗體契約製造市場的關鍵市場洞察

抗體契約製造市場正在因供需的動態相互作用而發生轉變。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 生物製藥療法的開發和商業化的需求
    • 對治療慢性疾病的先進抗體的需求不斷成長
    • 對個人化藥物的偏好日益成長
  • 市場限制因素
    • 對生技藥品開發和製造的擔憂
  • 市場機會
    • 增加生技藥品管道並擴大契約製造服務
    • 全球抗體生產研發預算增加
  • 市場挑戰
    • 雙/多特異性抗體形式的複雜性

波特的五力戰略工具駕馭契約製造市場

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解抗體契約製造市場的外部影響

外部宏觀環境因素在塑造抗體契約製造市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解抗體契約製造市場的競爭狀況

抗體契約製造市場的詳細市場佔有率分析提供了對供應商績效的全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣抗體契約製造市場供應商績效評估

FPNV定位矩陣是評估抗體契約製造市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，描繪抗體契約製造市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對抗體契約製造市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 生物製藥療法的開發和商業化的需求
      • 對治療慢性疾病的先進抗體的需求不斷成長
      • 對個人化醫療的興趣日益濃厚
    • 抑制因素
      • 對生技藥品開發和製造的擔憂
    • 機會
      • 增加生物製藥管道並擴大契約製造服務
      • 增加全球抗體生產的研發預算
    • 任務
      • 雙/多特異性抗體形式的複雜性
  • 市場區隔分析
    • 抗體類型：單株抗體因其同質性、特異性和大規模生產能力而受到很高的需求。
    • 最終用戶：抗體契約製造擴大被生物技術和製藥公司採用，以利用他們在抗體生產和精製的專業知識。
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章 按抗體類型分類的抗體契約製造市場

  • 單株抗體
  • 多株抗體

第7章 抗體契約製造市場：依來源分類

  • 哺乳動物的
  • 微生物

第8章抗體契約製造市場：依服務分類

  • 分析開發和品管
  • 細胞株開發
  • 製程開發

第9章 抗體契約製造市場：依最終用戶分類

  • 學術研究機構
  • 生物技術和製藥公司

第10章 北美和南美抗體契約製造市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太抗體契約製造市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章 歐洲、中東和非洲的抗體契約製造市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • 三星生物製品公司與 LEGOChem Biosciences 建立策略夥伴關係，加速固態腫瘤治療的 ADC 創新
    • Aragen 在班加羅爾工廠投資 3,000 萬美元，加強生物製藥生產能力
    • KBI Biopharma 推出 SUREmAb，單株抗體開發與加速製造解決方案
  • 戰略分析和建議

公司名單

  • Abeomics
  • Absolute Antibody by LSBio
  • Advanced ChemTech, Inc.
  • AGC Biologics
  • Antibodies, Inc.
  • AstraZeneca
  • Boehringer Ingelheim Biopharmaceuticals GmbH.
  • Bryllan LLC
  • Catalent, Inc.
  • CD BioSciences
  • Charles River Laboratories International, Inc.
  • Eli Lilly and Company
  • FUJIFILM Holdings Corporation
  • Fujirebio Inc. by HU Group Holdings, Inc.
  • Hycult Biotechnology（HBT）BV
  • Labcorp Drug Development
  • Lonza Group Ltd.
  • Merck KGaA
  • Molecular Depot LLC
  • Pierre Fabre SA
  • Samsung Biologics
  • Sapphire Bioscience Pty. Ltd.
  • Scantibodies Laboratory, Inc.
  • Synthon International Holding BV
  • The Serum Institute of India
  • WuXi Biologics Co., Ltd.
Product Code: MRR-742BD517AE6B

The Antibodies Contract Manufacturing Market was valued at USD 16.34 billion in 2023, expected to reach USD 18.04 billion in 2024, and is projected to grow at a CAGR of 10.82%, to USD 33.56 billion by 2030.

Antibodies contract manufacturing involves outsourcing the production of antibodies, crucial for therapeutic, diagnostic, and research purposes, to specialized third-party organizations. The necessity for antibodies manufacturing arises from the increasing prevalence of chronic diseases, the growing importance of personalized medicine, and the demand for novel therapeutics, which together underscore the need for scalable, reliable production capabilities. Applications span across pharmaceuticals, biotechnology, academic research, and diagnostics, with end-use predominantly in therapeutic monoclonal antibodies, polyclonal antibodies, biosimilars, and antibody fragments. Key growth influencers include advancements in biotechnology, the rise of biologics, and the expansion of healthcare infrastructure globally. Moreover, technological innovations, such as high-throughput screening and improved expression systems, propel market expansion. Current opportunities lie in untapped markets in emerging economies where demand for advanced healthcare solutions is rising and in niches like bispecific antibodies and antibody-drug conjugates. To seize these opportunities, businesses should focus on strategic partnerships and capacity expansion to accommodate the growing demand for diverse antibody types. However, the market faces challenges such as stringent regulatory frameworks, complex manufacturing processes, the high cost of production, and intellectual property rights issues. Addressing these barriers with efficient quality control systems and streamlined production technologies can mitigate risks. Innovations such as improvements in expression systems (e.g., CHO cells), sustainable production practices, and AI-driven process optimization offer the potential for substantial advancements. Exploring biosimilar antibodies and personalized medicine solutions also presents significant growth avenues. Overall, this market is characterized by rapid technological advancements and competitive dynamics, challenging companies to constantly innovate and adapt. By focusing on sustainable development, operational efficiency, and expanding global reach, businesses can position themselves advantageously within this thriving industry.

KEY MARKET STATISTICS
Base Year [2023] USD 16.34 billion
Estimated Year [2024] USD 18.04 billion
Forecast Year [2030] USD 33.56 billion
CAGR (%) 10.82%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Antibodies Contract Manufacturing Market

The Antibodies Contract Manufacturing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Development and commercialization need for biopharmaceutical therapeutics
    • Surging need for advanced antibodies for the treatment of chronic diseases
    • Rising preference for personalized medicines
  • Market Restraints
    • Concerns regarding development and manufacturing of biologics
  • Market Opportunities
    • Growing number of biologics pipelines and growing contract manufacturing service
    • Increasing the R&D budget for the production of antibodies globally
  • Market Challenges
    • Complexity of bi/multispecific antibody formats

Porter's Five Forces: A Strategic Tool for Navigating the Antibodies Contract Manufacturing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Antibodies Contract Manufacturing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Antibodies Contract Manufacturing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Antibodies Contract Manufacturing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Antibodies Contract Manufacturing Market

A detailed market share analysis in the Antibodies Contract Manufacturing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Antibodies Contract Manufacturing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Antibodies Contract Manufacturing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Antibodies Contract Manufacturing Market

A strategic analysis of the Antibodies Contract Manufacturing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Antibodies Contract Manufacturing Market, highlighting leading vendors and their innovative profiles. These include Abeomics, Absolute Antibody by LSBio, Advanced ChemTech, Inc., AGC Biologics, Antibodies, Inc., AstraZeneca, Boehringer Ingelheim Biopharmaceuticals GmbH., Bryllan LLC, Catalent, Inc., CD BioSciences, Charles River Laboratories International, Inc., Eli Lilly and Company, FUJIFILM Holdings Corporation, Fujirebio Inc. by H.U. Group Holdings, Inc., Hycult Biotechnology (H.B.T.) B.V., Labcorp Drug Development, Lonza Group Ltd., Merck KGaA, Molecular Depot LLC, Pierre Fabre S.A, Samsung Biologics, Sapphire Bioscience Pty. Ltd., Scantibodies Laboratory, Inc., Synthon International Holding B.V., The Serum Institute of India, and WuXi Biologics Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Antibodies Contract Manufacturing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Antibody Type, market is studied across Monoclonal Antibodies and Polyclonal Antibodies.
  • Based on Source, market is studied across Mammalian and Microbial.
  • Based on Services, market is studied across Analytical Development & Quality Control, Cell Line Development, and Process Development.
  • Based on End-User, market is studied across Academics & Research Institutions and Biotechnology & Pharmaceuticals Companies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Development and commercialization need for biopharmaceutical therapeutics
      • 5.1.1.2. Surging need for advanced antibodies for the treatment of chronic diseases
      • 5.1.1.3. Rising preference for personalized medicines
    • 5.1.2. Restraints
      • 5.1.2.1. Concerns regarding development and manufacturing of biologics
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing number of biologics pipelines and growing contract manufacturing service
      • 5.1.3.2. Increasing the R&D budget for the production of antibodies globally
    • 5.1.4. Challenges
      • 5.1.4.1. Complexity of bi/multispecific antibody formats
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Antibody Type: Growing need for monoclonal antibodies due to their uniformity, specificity, and large-scale production capabilities
    • 5.2.2. End-User: Rising adoption of antibodies contract manufacturing among biotechnology & pharmaceutical firms to leverage specialized expertise in antibody production and purification
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Antibodies Contract Manufacturing Market, by Antibody Type

  • 6.1. Introduction
  • 6.2. Monoclonal Antibodies
  • 6.3. Polyclonal Antibodies

7. Antibodies Contract Manufacturing Market, by Source

  • 7.1. Introduction
  • 7.2. Mammalian
  • 7.3. Microbial

8. Antibodies Contract Manufacturing Market, by Services

  • 8.1. Introduction
  • 8.2. Analytical Development & Quality Control
  • 8.3. Cell Line Development
  • 8.4. Process Development

9. Antibodies Contract Manufacturing Market, by End-User

  • 9.1. Introduction
  • 9.2. Academics & Research Institutions
  • 9.3. Biotechnology & Pharmaceuticals Companies

10. Americas Antibodies Contract Manufacturing Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Antibodies Contract Manufacturing Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Antibodies Contract Manufacturing Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Samsung Biologics and LegoChem Biosciences Forge Strategic Alliance to Accelerate ADC Innovation for Solid Tumor Treatment
    • 13.3.2. Aragen Invests USD 30 Million in Bangalore Facility to Boost Biologics Manufacturing Capabilities
    • 13.3.3. KBI Biopharma Unveils SUREmAb, Monoclonal Antibody Development with Accelerated Manufacturing Solutions
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abeomics
  • 2. Absolute Antibody by LSBio
  • 3. Advanced ChemTech, Inc.
  • 4. AGC Biologics
  • 5. Antibodies, Inc.
  • 6. AstraZeneca
  • 7. Boehringer Ingelheim Biopharmaceuticals GmbH.
  • 8. Bryllan LLC
  • 9. Catalent, Inc.
  • 10. CD BioSciences
  • 11. Charles River Laboratories International, Inc.
  • 12. Eli Lilly and Company
  • 13. FUJIFILM Holdings Corporation
  • 14. Fujirebio Inc. by H.U. Group Holdings, Inc.
  • 15. Hycult Biotechnology (H.B.T.) B.V.
  • 16. Labcorp Drug Development
  • 17. Lonza Group Ltd.
  • 18. Merck KGaA
  • 19. Molecular Depot LLC
  • 20. Pierre Fabre S.A
  • 21. Samsung Biologics
  • 22. Sapphire Bioscience Pty. Ltd.
  • 23. Scantibodies Laboratory, Inc.
  • 24. Synthon International Holding B.V.
  • 25. The Serum Institute of India
  • 26. WuXi Biologics Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. ANTIBODIES CONTRACT MANUFACTURING MARKET RESEARCH PROCESS
  • FIGURE 2. ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ANTIBODIES CONTRACT MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. ANTIBODIES CONTRACT MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANTIBODIES CONTRACT MANUFACTURING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTIBODIES CONTRACT MANUFACTURING MARKET DYNAMICS
  • TABLE 7. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY POLYCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY MAMMALIAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY MICROBIAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL DEVELOPMENT & QUALITY CONTROL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CELL LINE DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ACADEMICS & RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY & PHARMACEUTICALS COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 51. AUSTRALIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. AUSTRALIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 55. CHINA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. CHINA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. INDIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. INDIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. INDONESIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. INDONESIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. JAPAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. JAPAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. MALAYSIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. MALAYSIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. PHILIPPINES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. PHILIPPINES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. SINGAPORE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. SINGAPORE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. SOUTH KOREA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. SOUTH KOREA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. TAIWAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. TAIWAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. THAILAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. THAILAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. VIETNAM ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. VIETNAM ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 104. DENMARK ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. DENMARK ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 108. EGYPT ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. EGYPT ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 112. FINLAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. FINLAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 116. FRANCE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. FRANCE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 120. GERMANY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. GERMANY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. ISRAEL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. ISRAEL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 128. ITALY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. ITALY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. NETHERLANDS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. NETHERLANDS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 136. NIGERIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. NIGERIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 140. NORWAY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. NORWAY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. POLAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. POLAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 148. QATAR ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. QATAR ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 152. RUSSIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. RUSSIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 156. SAUDI ARABIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. SAUDI ARABIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 160. SOUTH AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 164. SPAIN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. SPAIN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 168. SWEDEN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. SWEDEN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 172. SWITZERLAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. SWITZERLAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 176. TURKEY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. TURKEY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 180. UNITED ARAB EMIRATES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. UNITED ARAB EMIRATES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED KINGDOM ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED KINGDOM ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 188. ANTIBODIES CONTRACT MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 189. ANTIBODIES CONTRACT MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2023